Efficiency of combining pomegranate juice with low-doses of cisplatin and taxotere on A549 human lung adenocarcinoma cells

Nasser Mohamad; Hijazi Akram; Sayed Bouchra; Jamal Zeinab; Ibrahim Sajida; Rammal Hassan; Sayed Bouchra; Al Rekaby Abd-el-ameer; Nasser Mohammed

Return

Efficiency of combining pomegranate juice with low-doses of cisplatin and taxotere on A549 human lung adenocarcinoma cells

Author: Nasser MOHAMAD ¹ ; Hijazi AKRAM ¹ ; Sayed BOUCHRA ¹ ; Jamal ZEINAB ¹ ; Ibrahim SAJIDA ¹ ; Rammal HASSAN ¹ ; Sayed BOUCHRA ² ; Al Rekaby ABD-EL-AMEER ³ ; Nasser MOHAMMED ⁴
Author Information

1. Doctoral School of Science and Technology, Research Platform for Environmental Science (PRASE), Lebanese University
2. Fédérale de Toulouse Midi-Pyrénées, INP-ENSIACET, Laboratoire de Chimie Agro-industrielle
3. Al Mustansiriya University, College of Science, Department of Biology
4. American University of Beirut
Publication Type:Journal Article
Keywords: A549 cells; Chemotherapy; Cisplatin; Lung cancer; Pomegranate; Taxotere
From:Asian Pacific Journal of Tropical Biomedicine 2018;7(1):19-24
CountryChina
Language:Chinese
Abstract: Objective: To test the coalescence effect of two chemotherapy drugs at low effective dose (cisplatin and taxotere) combined with pomegranate juice on A549 cancer cells. Methods: Infrared spectroscopy method is a qualitative test that was performed to ensure the existence of the phytochemicals providing the antioxidant activity through the presence of the hydroxyl group (-OH). The viability of A549 cell line and normal MCs was tested using the neutral red uptake, Clonogenic survival, XTT and Cell migration assays. Results: Our results showed that this combination firstly led to a greater decrease in the viability of cells comparing to those treated with chemotherapy drugs alone, and secondly led to a significant reduction in cell migration. Conclusions: These data suggest a synergistic effect between the pomegranate and cisplatin which makes probably this combination a powerful option for treating lung adenocarcinoma and in parallel minimizing the systemic side effects.